Shopping Cart
Remove All
Your shopping cart is currently empty
α-Conotoxin PIA TFA is an nAChR (nicotinic acetylcholine receptor) antagonist that primarily targets nAChR subtypes containing α6 and α3 subunits, exhibiting significantly higher selectivity for α6/α3β2β3 nAChR than α3β2 nAChR, and may be used for Parkinson's disease and schizophrenia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $322 | In Stock | In Stock | |
| 5 mg | $783 | In Stock | In Stock | |
| 10 mg | $1,090 | - | In Stock | |
| 25 mg | $1,620 | - | In Stock | |
| 50 mg | $2,190 | - | In Stock |
| Description | α-Conotoxin PIA TFA is an nAChR (nicotinic acetylcholine receptor) antagonist that primarily targets nAChR subtypes containing α6 and α3 subunits, exhibiting significantly higher selectivity for α6/α3β2β3 nAChR than α3β2 nAChR, and may be used for Parkinson's disease and schizophrenia. |
| Molecular Weight | 2095.3 |
| Formula | C81H126F3N27O27S4 |
| Smiles | O=C1N2[C@](CCC2)([H])C(N[C@H](C(N[C@@](C(N[C@@H](CSSC[C@]3([H])NC([C@H](CSSC[C@@](NC([C@@H](NC([C@@]4([H])N(CCC4)C([C@@H](NC([C@@H](NC3=O)CO)=O)CC(N)=O)=O)=O)C(C)C)=O)([H])C(N[C@@](C(N[C@H](C(N[C@H](C(N[C@H]1CC(N)=O)=O)CC5=CN=CN5)=O)C(C)C)=O)([H])[C@H](O)C)=O)NC([C@H]6N(CCC6)C([C@H](CC(O)=O)NC([C@@H](N)CCCNC(N)=N)=O)=O)=O)=O)C(N)=O)=O)([H])[C@@H](C)CC)=O)CCC(N)=O)=O.O=C(C(F)(F)F)O |
| Color | White |
| Appearance | Solid |
| Sequence | Arg-Asp-Pro-Cys-Cys-Ser-Asn-Pro-Val-Cys-Thr-Val-His-Asn-Pro-Gln-Ile-Cys-NH2 (Disulfide bridge:Cys4-Cys10;Cys5-Cys18) |
| Sequence Short | RDPCCSNPVCTVHNPQIC-NH2 (Disulfide bridge:Cys4-Cys10;Cys5-Cys18) |
| Storage | keep away from moisture | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: ≥ 200 mg/mL, Sonication is recommended. |
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (0.95 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.